Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 3/20 | 0.33 |
| ▸ | CTSG | P08311 | 3/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.33 |
| ▸ | CMA1 | P23946 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 2/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18999245 | 0.81 | CTSK (0.35) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL18982928 | 0.77 | KMT2A (0.33) | LMNAMEN1OPRM1OPRD1KMT2A | |
| SCHEMBL19006349 | 0.76 | USP2 (0.35) | PRSS1CTSGCTRB1CMA1USP2 | |
| SCHEMBL19006348 | 0.74 | MEN1 (0.39) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL19031893 | 0.74 | — | — | |
| SCHEMBL18982387 | 0.73 | SLC6A2 (0.34) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL19006275 | 0.69 | CYP1A2 (0.35) | — | |
| SCHEMBL18982267 | 0.68 | MEN1 (0.36) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL18982161 | 0.65 | — | — | |
| SCHEMBL18982722 | 0.65 | MEN1 (0.31) | MEN1OPRM1OPRD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | PRSS1 1508/4885CTSG 3389/4885CTRB1 2290/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | PRSS1 1508/4885CTSG 3389/4885CTRB1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.